Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)(09/26/16 )


BOSTON, MA — (Marketwired) — 09/26/16 — Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary

Anticalin® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference – Translating Science into Survival, taking place in New York City.

Click here to visit Pieris Pharmaceuticals, Inc. http://ir.pieris.com/press-releases/detail/543